At Senate confirmation hearing for NIH directorship, Bertagnolli focuses on clinical trials, data analytics, health equity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

At a Senate hearing that considered her nomination to the post of NIH director, Monica Bertagnolli laid out an agenda that includes expanding access to clinical trials and making health care innovation affordable and accessible to the public.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Alexandria Carolan
Alexandria Carolan
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login